Skip to main content

Advertisement

Log in

Influence of dose reduction of vincristine in R-CHOP on outcomes of diffuse large B cell lymphoma

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Dose intensity (DI) of chemotherapy affects prognosis of diffuse large B cell lymphoma (DLBCL). Myelotoxicity is the major dose-limiting toxicity (DLT) of most cytotoxic agents for hematological malignancies, whereas DLT of vincristine (VCR) is mainly neurological toxicity. Although VCR is a key drug and its combination with other cytotoxic agents needs consideration, studies focused on relative DI (RDI) of VCR have not been done before. We retrospectively analyzed 86 cases of DLBCL that received six or more cycles of cyclophosphamide (CPM), doxorubicin (DXR), VCR, prednisolone, and rituximab [R-CHOP] and calculated RDI of each cytotoxic agent to analyze its influence on treatment outcome. The median RDI of CPM, doxorubicin, and VCR was 80.0, 81.7, and 78.4 %, respectively (p = 0.002). The average RDI (ARDI) of these three agents was 80.0 %. The overall survival was significantly worse in the low ARDI (<85 %) than in the high ARDI (>85 %) group (2-year survival rate 67.2 vs 93.4 %, p = 0.011). The survival rate with low RDI VCR (<85 %) was lower than that with high RDI VCR (>85 %), even when the remaining two agents had high ARDI (2-year survival rate 74.3 vs 95.8 %, p = 0.047). In conclusion, VCR dose tended to be reduced compared with CPM and DXR in R-CHOP. Lower ARDI of cytotoxic agents and lower RDI of VCR could lead to poor prognosis in the treatment of DLBCL with R-CHOP. We thought these observations should be confirmed in a prospective study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Swerdlow SH, International Agency for Research on Cancer, World Health Organization (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. World Health Organization classification of tumours, 4th edn. International Agency for Research on Cancer, Lyon, France

    Google Scholar 

  2. Aoki R, Karube K, Sugita Y, Nomura Y, Shimizu K, Kimura Y, Hashikawa K, Suefuji N, Kikuchi M, Ohshima K (2008) Distribution of malignant lymphoma in Japan: analysis of 2260 cases, 2001–2006. Pathol Int 58(3):174–182. doi:10.1111/j.1440-1827.2007.02207.x

    Article  PubMed  Google Scholar 

  3. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235–242. doi:10.1056/NEJMoa011795, 346/4/235 [pii]

    Article  PubMed  CAS  Google Scholar 

  4. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993). N Engl J Med 329 (14):987–994. doi:10.1056/NEJM199309303291402

  5. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109(5):1857–1861. doi:10.1182/blood-2006-08-038257

    Article  PubMed  CAS  Google Scholar 

  6. Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson M, Niland J, Gascoyne RD, Connors JM, Friedberg JW, Winter JN (2014) An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 123(6):837–842. doi:10.1182/blood-2013-09-524108

    Article  PubMed  CAS  Google Scholar 

  7. Terada Y, Nakamae H, Aimoto R, Kanashima H, Sakamoto E, Aimoto M, Inoue E, Koh H, Nakane T, Takeoka Y, Ohsawa M, Koh KR, Yamane T, Nakao Y, Ohta K, Mugitani A, Teshima H, Hino M (2009) Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma. J Exp Clin Cancer Res 28:116. doi:10.1186/1756-9966-28-116

    Article  PubMed  PubMed Central  Google Scholar 

  8. Hirakawa T, Yamaguchi H, Yokose N, Gomi S, Inokuchi K, Dan K (2010) Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma. Ann Hematol 89(9):897–904. doi:10.1007/s00277-010-0956-7

    Article  PubMed  CAS  Google Scholar 

  9. Borel C, Lamy S, Compaci G, Recher C, Jeanneau P, Nogaro JC, Bauvin E, Despas F, Delpierre C, Laurent G (2015) A longitudinal study of non-medical determinants of adherence to R-CHOP therapy for diffuse large B-cell lymphoma: implication for survival. BMC Cancer 15(1):288. doi:10.1186/s12885-015-1287-9

    Article  PubMed  PubMed Central  Google Scholar 

  10. Gutierrez A, Bento L, Bautista-Gili AM, Garcia F, Martinez-Serra J, Sanchez B, Martorell C, Gines J, Garcia L, Gimeno E, Ferraro M, Del Campo R, Bargay J, Perez A, Vercher J, Scaff M, Pacheco A, Ballester C, Garcia F, Ramos R, Salar A, Besalduch J (2015) Differential impact of relative dose-intensity reductions in diffuse large B-cell lymphoma treated with R-CHOP21 or R-CHOP14. PLoS One 10(4):e0123978. doi:10.1371/journal.pone.0123978

    Article  PubMed  PubMed Central  Google Scholar 

  11. Carbone PP, Bono V, Frei E 3rd, Brindley CO (1963) Clinical studies with vincristine. Blood 21:640–647

    PubMed  CAS  Google Scholar 

  12. Jackson DV Jr, Sethi VS, Spurr CL, Willard V, White DR, Richards F 2nd, Stuart JJ, Muss HB, Cooper MR, Homesley HD, Jobson VW, Castle MC (1981) Intravenous vincristine infusion: phase I trial. Cancer 48(12):2559–2564

    Article  PubMed  Google Scholar 

  13. Haim N, Epelbaum R, Ben-Shahar M, Yarnitsky D, Simri W, Robinson E (1994) Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas. Cancer 73(10):2515–2519

    Article  PubMed  CAS  Google Scholar 

  14. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA, Alliance AL, Lymphoma G, Eastern Cooperative Oncology G, European Mantle Cell Lymphoma C, Italian Lymphoma F, European Organisation for R, Treatment of Cancer/Dutch Hemato-Oncology G, Grupo Espanol de Medula O, German High-Grade Lymphoma Study G, German Hodgkin’s Study G, Japanese Lymphorra Study G, Lymphoma Study A, Group NCT, Nordic Lymphoma Study G, Southwest Oncology G, Southwest Oncology G, United Kingdom National Cancer Research I (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059–3068. doi:10.1200/JCO.2013.54.8800

    Article  PubMed  Google Scholar 

  15. Epelbaum R, Haim N, Ben-Shahar M, Ron Y, Cohen Y (1988) Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma. Isr J Med Sci 24(9–10):533–538

    PubMed  CAS  Google Scholar 

  16. Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, Moore A, Ellerton JA, Norton L, Ferree CR et al (1994) Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330(18):1253–1259. doi:10.1056/NEJM199405053301801

    Article  PubMed  CAS  Google Scholar 

  17. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 332(14):901–906. doi:10.1056/NEJM199504063321401

    Article  PubMed  CAS  Google Scholar 

  18. Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI (2004) Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study. J Clin Oncol 22(21):4302–4311. doi:10.1200/JCO.2004.03.213

    Article  PubMed  CAS  Google Scholar 

  19. Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48(3):452–458. doi:10.1038/bmt.2012.244

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  20. Kwak LW, Halpern J, Olshen RA, Horning SJ (1990) Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 8(6):963–977, RDI of CHOP

    PubMed  CAS  Google Scholar 

  21. Lee KW, Kim DY, Yun T, Kim DW, Kim TY, Yoon SS, Heo DS, Bang YJ, Park S, Kim BK, Kim NK (2003) Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage. Cancer 98(12):2651–2656. doi:10.1002/cncr.11846

    Article  PubMed  CAS  Google Scholar 

  22. Bosly A, Bron D, Van Hoof A, De Bock R, Berneman Z, Ferrant A, Kaufman L, Dauwe M, Verhoef G (2008) Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol 87(4):277–283. doi:10.1007/s00277-007-0399-y

    Article  PubMed  CAS  Google Scholar 

  23. Epelbaum R, Faraggi D, Ben-Arie Y, Ben-Shahar M, Haim N, Ron Y, Robinson E, Cohen Y (1990) Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables. Cancer 66(6):1124–1129

    Article  PubMed  CAS  Google Scholar 

  24. Yamaguchi H, Hirakawa T, Inokuchi K (2011) Importance of relative dose intensity in chemotherapy for diffuse large B-cell lymphoma. J Clin Exp Hematop 51(1):1–5

    Article  PubMed  Google Scholar 

  25. Lyman GH, Dale DC, Culakova E, Poniewierski MS, Wolff DA, Kuderer NM, Huang M, Crawford J (2013) The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 24(10):2475–2484. doi:10.1093/annonc/mdt226

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  26. Balducci L, Mo M, Abella E, Saven A (2014) Retrospective analysis of relative dose intensity in patients with non-Hodgkin lymphoma receiving CHOP-based chemotherapy and pegfilgrastim. Am J Clin Oncol 37(6):603–610. doi:10.1097/COC.0000000000000141

    Article  PubMed  CAS  Google Scholar 

  27. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 328(14):1002–1006. doi:10.1056/NEJM199304083281404

    Article  PubMed  CAS  Google Scholar 

  28. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP (1994) A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin’s lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Ann Oncol 5(2):91–95

    Article  PubMed  Google Scholar 

  29. Sertoli MR, Santini G, Chisesi T, Congiu AM, Rubagotti A, Contu A, Salvagno L, Coser P, Porcellini A, Vespignani M et al (1994) MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin’s lymphoma: results of a prospective randomized trial by the non-Hodgkin’s Lymphoma Cooperative Study Group. J Clin Oncol 12(7):1366–1374

    PubMed  CAS  Google Scholar 

  30. Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, Bologna S, Ghesquieres H, Hacini M, Fruchart C, Ysebaert L, Ferme C, Casasnovas O, Van Hoof A, Thyss A, Delmer A, Fitoussi O, Molina TJ, Haioun C, Bosly A (2013) Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol 14(6):525–533. doi:10.1016/S1470-2045(13)70122-0

    Article  PubMed  CAS  Google Scholar 

  31. Silverman JA, Reynolds L, Deitcher SR (2013) Pharmacokinetics and pharmacodynamics of vincristine sulfate liposome injection (VSLI) in adults with acute lymphoblastic leukemia. J Clin Pharmacol 53(11):1139–1145. doi:10.1002/jcph.155

    PubMed  CAS  Google Scholar 

  32. Thomas DA, Kantarjian HM, Stock W, Heffner LT, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Pierce S, Lu B, Deitcher SR, O’Brien S (2009) Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia. Cancer 115(23):5490–5498. doi:10.1002/cncr.24632

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  33. O’Brien S, Schiller G, Lister J, Damon L, Goldberg S, Aulitzky W, Ben-Yehuda D, Stock W, Coutre S, Douer D, Heffner LT, Larson M, Seiter K, Smith S, Assouline S, Kuriakose P, Maness L, Nagler A, Rowe J, Schaich M, Shpilberg O, Yee K, Schmieder G, Silverman JA, Thomas D, Deitcher SR, Kantarjian H (2013) High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol 31(6):676–683. doi:10.1200/JCO.2012.46.2309

    Article  PubMed  Google Scholar 

  34. Hagemeister F, Rodriguez MA, Deitcher SR, Younes A, Fayad L, Goy A, Dang NH, Forman A, McLaughlin P, Medeiros LJ, Pro B, Romaguera J, Samaniego F, Silverman JA, Sarris A, Cabanillas F (2013) Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®)) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. Br J Haematol 162(5):631–638. doi:10.1111/bjh.12446

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We would like to thank all the patients who took part in this study.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yoshikazu Utsu.

Ethics declarations

Formal consent is not required for this type of study.

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Utsu, Y., Takaishi, K., Inagaki, S. et al. Influence of dose reduction of vincristine in R-CHOP on outcomes of diffuse large B cell lymphoma. Ann Hematol 95, 41–47 (2016). https://doi.org/10.1007/s00277-015-2514-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-015-2514-9

Keywords

Navigation